ClinicalTrials.gg
CompletedNCT03444103Updated Sep 9, 2020

A Pilot Trial of Clazakizumab in Late ABMR

A Phase 2 interventional study of Clazakizumab / Clazakizumab and Placebo / Clazakizumab in Antibody-mediated Rejection, sponsored by Medical University of Vienna. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Medical University of Vienna · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This bi-center study (Medical University of Vienna \& Charité Berlin) is an investigator-driven pilot trial designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy (preliminary assessment) of humanized anti-IL-6 monoclonal antibody clazakizumab in kidney transplant recipients with late antibody-mediated rejection (ABMR). The study is designed as a phase 2 trial and has two subsequent sub-parts, a randomized placebo-controlled trial (part A) of 12 weeks, where recipients are allocated to receive either anti-IL-6 antibody clazakizumab (n=10) or placebo (n=10), followed by an open-label prospective study, where all 20 study patients will receive clazakizumab for a period of 40 weeks. Study protocol biopsies will be performed at the end of part A and part B.

Read the detailed description

Part A:

Patients positive for anti-HLA donor-specific antibodies (DSA) and with biopsy-proven late ABMR (Acute/active or chronic/active phenotype according to the Banff 2015 classification) will be identified and recruited at the kidney transplantation outpatient services of the two center sites. Participants will be randomized to receive either clazakizumab or placebo subcutaneously (1:1 randomization stratified for ABMR type) for a period of 12 weeks (administration of clazakizumab/placebo at day 0, and after 4 and 8 weeks). After 12 weeks, patients will be subjected to a first follow-up biopsy. Primary goals of this part of the trial are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a short course of treatment. Moreover, part A will allow for a first preliminary assessment of the impact of clazakizumab on ABMR-associated inflammation detected in peripheral blood and in the rejecting organ allograft, on the pharmacokinetics of pantoprazole as a probe drug to investigate influence of IL-6 blockade on cytochrome P450 (CYP) dependent drug metabolism (potential effects on the half-life of CYP-metabolized drugs such as pantoprazole, and on the short-term course of DSA mean fluorescence intensity (MFI) and kidney allograft function (eGFR, urinary protein excretion). The randomization sequence will be unblinded for a first data analysis after the last patient has completed the 12-week follow-up period.

Part B:

After completion of part A after 12 weeks, all study patients will enter part B, an open-label part of the study. All 20 subjects will receive subcutaneous clazakizumab in 4-weekly intervals until the end-of-study (EOS) visit after 52 weeks and will then be subjected to a second protocol biopsy. Major goals of part B are to evaluate the safety and tolerability of a prolonged period of treatment with clazakizumab and the long-term impact of this antibody on the evolution of ABMR, rejection-associated biomarkers and kidney allograft function and survival over a period of 12 months.

02

Conditions studied

  • Antibody-mediated Rejection

Keywords

  • IL-6 blockade
03

In context

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written
  • Age >18 years
  • Functioning living or deceased donor allograft after ≥365 days post-transplantation
  • >30 ml/min/1.73 m2
  • Detection of HLA class I and/or II antigen-specific antibodies (preformed and/or de novo DSA).
  • Acute/active or chronic/active ABMR (±C4d in PTC) according to Banff 2013/2015
  • Molecular ABMR score (ABMRpm) ≥0.2

Exclusion criteria

Exclusion Criteria:

  • Patients actively participating in another clinical trial
  • Age ≤18 years
  • Female subject is pregnant or lactating
  • Index results:
  • T-cell-mediated rejection classified Banff grade ≥I
  • De novo or recurrent severe thrombotic microangiopathy
  • Polyoma virus nephropathy
  • De novo or recurrent glomerulonephritis
  • Acute rejection treatment \<3 month before screening
  • Acute deterioration of graft function ( decline within 1-3 months >25%)
  • Nephrotic range proteinuria >3500 mg/g protein/creatinine ratio
  • Active viral, bacterial or fungal infection precluding intensified
  • Active malignant disease precluding intensified immunosuppressive therapy
  • Abnormal liver function tests (, AST, > 1.5 x )
  • Other significant liver disease
  • Latent or active tuberculosis (positive QuantiFERON-TB-Gold test, Chest X-ray)
  • Administration of a within 6 weeks of screening
  • Neutropenia (\<1 G/L) or thrombocytopenia (\<100 G/L)
  • History of gastrointestinal perforation, diverticulitis, or inflammatory bowel disease
  • Allergy against proton pump inhibitors
  • History of alcohol or illicit substance abuse
  • Serious medical or psychiatric illness likely to interfere with participation in the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Clazakizumab / Clazakizumab

    Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).

    Drug: Clazakizumab / Clazakizumab

  • Placebo comparator
    Placebo / Clazakizumab

    Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).

    Drug: Placebo / Clazakizumab

Interventions

  • DrugClazakizumab / Clazakizumab

    Drug page: Clazakizumab

    Humanized monoclonal anti-IL-6 antibody

    Also known as: Anti-IL-6 antibody

  • DrugPlacebo / Clazakizumab

    0.9% Saline

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Number of adverse events and severe adverse events (AE's, SAE's)

    Serious and Non-Serious adverse events probably or possibly attributable to clazakizumab

    Time frame: 12 months

Secondary outcomes

  1. Anti-clazakizumab antibodies in serum

    - Concentration of anti-clazakizumab antibodies in serum (ng/mL)

    Time frame: At 0, 12 and 52 weeks

  2. Clazakizumab serum concentration

    - Total clazakizumab serum concentration (ng/mL)

    Time frame: At 0, 12 and 52 weeks

  3. Pantoprazole serum concentration

    - Effect of clazakizumab on pantoprazole serum concentration (nanogram per mL)

    Time frame: At 0, 12 and 52 weeks

  4. Protocol biopsy results - microcirculation inflammation

    - Microcirculation inflammation (g+ptc score), scale 0-3, higher = worse prognosis

    Time frame: At week 11 and at week 52

  5. Protocol biopsy results - chronic damage

    - Transplant glomerulopathy (cg) and interstitial fibrosis/tubular atrophy (IFTA) scores, scale 0-3, higher = worse prognosis

    Time frame: At week 11 and at week 52

  6. Protocol biopsy results - molecular signs of ABMR

    - Molecular ABMR score (molecular microscope, MMDx), scale 0-1 in 0.1 steps, higher = worse prognosis

    Time frame: At week 11 and at week 52

  7. Protocol biopsy results - ABMR phenotype

    - Archetype analysis of gene expression profiles (molecular microscope, MMDx), ABMR archetype score, scale 0-1 in 0.1 steps, higher = worse prognosis

    Time frame: At week 11 and at week 52

  8. Anti-HLA antibody levels - antibody strength

    - Maximum and sum of mean fluorescence intensity (MFI) of DSA (Luminex) - higher is worse

    Time frame: At 0, 12 and 52 weeks

  9. Anti-HLA antibody levels - number of DSA

    - Number of DSA (Luminex) - more is worse

    Time frame: At 0, 12 and 52 weeks

  10. Anti-HLA antibody levels - broadness of antibody reactivity

    - Broadness of sensitization (virtual PRA, Luminex), scale: %, higher = worse

    Time frame: At 0, 12 and 52 weeks

  11. Allograft function - eGFR

    - Estimated GFR (CKD-EPI, mL/min/1.73m2)

    Time frame: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52

  12. Allograft function - protein excretion in spot urine

    - Urinary protein excretion in spot urine (protein/creatinine ratio in mg/g)

    Time frame: At day 0, week 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 51 and 52

  13. Total IgG concentration

    - Nephelometry, mg/dL

    Time frame: At 0, 12 and 52 weeks

  14. Total IgM concentration

    - Nephelometry, mg/dL

    Time frame: At 0, 12 and 52 weeks

  15. Total IgA concentration

    - Nephelometry, mg/dL

    Time frame: At 0, 12 and 52 weeks

  16. IgG subclass 1 (IgG1)

    - ELISA, mg/dL

    Time frame: At 0, 12 and 52 weeks

  17. IgG subclass 2 (IgG2)

    - ELISA, mg/dL

    Time frame: At 0, 12 and 52 weeks

  18. IgG subclass 3 (IgG3)

    - ELISA, mg/dL

    Time frame: At 0, 12 and 52 weeks

  19. IgG subclass 4 (IgG4)

    - ELISA, mg/dL

    Time frame: At 0, 12 and 52 weeks

  20. Effect on leukocyte subsets in peripheral blood

    - Fluorescence intensity (0 to no upper limit)

    Time frame: At 0, 12 and 52 weeks

  21. Cytokine patterns and endothelial activation/injury markers in serum

    - Luminex bead panels, mean fluorescence intensities (MFI)

    Time frame: At 0, 12 and 52 weeks

  22. Effect on IL-6 gene expression in peripheral blood cells

    rtPCR

    Time frame: At 0, 12 and 52 weeks

  23. Effect on IL-6R gene expression in peripheral blood cells

    rtPCR

    Time frame: At 0, 12 and 52 weeks

  24. Patient survival

    Death: number of events, time to event

    Time frame: 12 months

  25. Graft survival

    Graft loss: number of events, time to event

    Time frame: 12 months

  26. Occurrence of biopsy-proven acute rejection necessitating rejection treatment

    Number of anti-rejection treatments with a substance other than the study drug

    Time frame: At week 52

07

Study locations

2 sites
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Charité University
    Berlin, 10117, Germany
08

References and documents

Publications

  • Mease PJ, Gottlieb AB, Berman A, Drescher E, Xing J, Wong R, Banerjee S. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68(9):2163-73. doi: 10.1002/art.39700. PubMed 27059799 ↗
  • Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, Kahwaji J, Reinsmoen N, Toyoda M, Jordan SC. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017 Sep;17(9):2381-2389. doi: 10.1111/ajt.14228. Epub 2017 Mar 10. PubMed 28199785 ↗
  • Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, Hidalgo LG, Haslacher H, Kaltenecker CC, Aretin MB, Oberbauer R, Posch M, Staudenherz A, Handisurya A, Reeve J, Halloran PF, Bohmig GA. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018 Feb;29(2):591-605. doi: 10.1681/ASN.2017070818. Epub 2017 Dec 14. PubMed 29242250 ↗
  • Mayer KA, Doberer K, Halloran PF, Budde K, Haindl S, Muhlbacher J, Eskandary F, Viard T, Casas S, Jilma B, Bohmig GA. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10. Transplant Direct. 2022 Nov 10;8(12):e1406. doi: 10.1097/TXD.0000000000001406. eCollection 2022 Dec. PubMed 36382130 ↗
  • Muhlbacher J, Schorgenhofer C, Doberer K, Durr M, Budde K, Eskandary F, Mayer KA, Schranz S, Ely S, Reiter B, Chong E, Adler SH, Jilma B, Bohmig GA. Anti-interleukin-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transpl Int. 2021 Aug;34(8):1542-1552. doi: 10.1111/tri.13954. Epub 2021 Jul 8. PubMed 34153143 ↗
  • Eskandary F, Durr M, Budde K, Doberer K, Reindl-Schwaighofer R, Waiser J, Wahrmann M, Regele H, Spittler A, Lachmann N, Firbas C, Muhlbacher J, Bond G, Halloran PF, Chong E, Jilma B, Bohmig GA. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 2019 Jan 11;20(1):37. doi: 10.1186/s13063-018-3158-6. PubMed 30635033 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jun 2020, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2018
First posted
Feb 23, 2018
StartActual
Jan 16, 2018
Primary completionActual
Jun 30, 2020
CompletionActual
Jun 30, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03444103
Responsible party
Farsad Eskandary (Principal Investigator, Medical University of Vienna) — Principal investigator
First posted
Feb 23, 2018
Start date
Jan 16, 2018
Primary completion
Jun 30, 2020
Completion
Jun 30, 2020
Last update
Sep 9, 2020

Study contacts

Bernd Jilma, MD
principal investigator · Department of Clinical Pharmacology, Medical University Vienna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion